[Bacteriological aspects in the mid term report of the CDTR clinical trial for PRSP and BLNAR infections].
Ubukata
K
K
D000208:Acute Disease; D000668:Ampicillin Resistance; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D006192:Haemophilus Infections / Q000188:drug therapy / Q000382:microbiology*; D006193:Haemophilus influenzae / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D007223:Infant; D010033:Otitis Media / Q000188:drug therapy / Q000382:microbiology*; D010403:Penicillin Resistance; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification*; D001618:beta-Lactamases
D002511:Cephalosporins; C073460:cefditoren; D001618:beta-Lactamases